While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Recent breakthroughs in understanding the prostaglandin D2 (PGD2) receptor 1 (DP1) are paving the way for innovative ...

Veozah (fezolinetant) was approved in 2023 by the FDA to treat moderate to severe hot flashes. A similar drug, elinzanetant, ...

When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the ...

A new three-drug combination could help women with a common form of aggressive breast cancer live longer, research suggests.

Dopamine, a small molecule derived from the amino acid tyrosine, plays a significant role in regulating multiple essential ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

The compound provides non-opioid pain relief by targeting neurotensin receptor 1 (NTSR1) on sensory neurons and within the ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

Mouse models treated with the sleep aid lemborexant had less brain damage compared to controls and mice that received a ...

Many patients with ER-positive/HER2-negative advanced breast cancer eventually develop resistance to standard first-line ...

The author, a doctor who works in addiction medicine at Brigham and Women's Hospital, urges RI's lawmakers to maintain the ...